Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 19567678)

1.

Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.

Zhang Y, Byun Y, Ren YR, Liu JO, Laterra J, Pomper MG.

Cancer Res. 2009 Jul 15;69(14):5867-75. doi: 10.1158/0008-5472.CAN-08-4866. Epub 2009 Jun 30.

2.

ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.

Zhang Y, Bressler JP, Neal J, Lal B, Bhang HE, Laterra J, Pomper MG.

Cancer Res. 2007 Oct 1;67(19):9389-97.

3.
4.

C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG.

Biochem Pharmacol. 2007 Jun 30;74(1):41-53. Epub 2007 Apr 1.

PMID:
17481587
5.

Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.

Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20801-6. doi: 10.1073/pnas.1312159110. Epub 2013 Dec 2.

6.
7.

A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.

Antczak C, Wee B, Radu C, Bhinder B, Holland EC, Djaballah H.

Assay Drug Dev Technol. 2014 Jan-Feb;12(1):28-42. doi: 10.1089/adt.2013.521. Epub 2013 Aug 30.

8.

Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS.

Cancer Res. 2011 Apr 15;71(8):3029-41. doi: 10.1158/0008-5472.CAN-10-3820. Epub 2011 Mar 14.

9.

Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.

Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR Jr, Ambudkar SV, Bates SE, Fu LW, Chen ZS.

Int J Biochem Cell Biol. 2014 Jun;51:111-9. doi: 10.1016/j.biocel.2014.03.026. Epub 2014 Apr 12.

PMID:
24726739
10.

A high-throughput cell-based assay for inhibitors of ABCG2 activity.

Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, Wilson JA, McMahon JB.

J Biomol Screen. 2006 Mar;11(2):176-83. Epub 2006 Feb 20.

PMID:
16490770
11.

A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.

Strouse JJ, Ivnitski-Steele I, Khawaja HM, Perez D, Ricci J, Yao T, Weiner WS, Schroeder CE, Simpson DS, Maki BE, Li K, Golden JE, Foutz TD, Waller A, Evangelisti AM, Young SM, Chavez SE, Garcia MJ, Ursu O, Bologa CG, Carter MB, Salas VM, Gouveia K, Tegos GP, Oprea TI, Edwards BS, Aubé J, Larson RS, Sklar LA.

J Biomol Screen. 2013 Jan;18(1):26-38. doi: 10.1177/1087057112456875. Epub 2012 Aug 24.

12.

Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.

Robey RW, Obrzut T, Shukla S, Polgar O, Macalou S, Bahr JC, Di Pietro A, Ambudkar SV, Bates SE.

Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83. doi: 10.1007/s00280-008-0908-2. Epub 2009 Jan 9.

13.

Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.

Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, Chen SP, Liang YJ, Cheng C, To KK, Fu LW.

Mol Med. 2012 Jul 18;18:887-98. doi: 10.2119/molmed.2011.00444.

14.

ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.

Wang F, Liang YJ, Wu XP, Su XD, Fu LW.

Chin J Cancer. 2012 Mar;31(3):150-8. doi: 10.5732/cjc.011.10310. Epub 2012 Feb 24.

15.

Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.

Valdameri G, Pereira Rangel L, Spatafora C, Guitton J, Gauthier C, Arnaud O, Ferreira-Pereira A, Falson P, Winnischofer SM, Rocha ME, Tringali C, Di Pietro A.

ACS Chem Biol. 2012 Feb 17;7(2):322-30. doi: 10.1021/cb200435y. Epub 2011 Nov 11.

PMID:
22039929
16.

The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.

Holland ML, Lau DT, Allen JD, Arnold JC.

Br J Pharmacol. 2007 Nov;152(5):815-24. Epub 2007 Oct 1.

17.

The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.

Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, Baer MR.

PLoS One. 2013 Aug 14;8(8):e71266. doi: 10.1371/journal.pone.0071266. eCollection 2013.

18.

OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.

Kuang YH, Patel JP, Sodani K, Wu CP, Liao LQ, Patel A, Tiwari AK, Dai CL, Chen X, Fu LW, Ambudkar SV, Korlipara VL, Chen ZS.

Biochem Pharmacol. 2012 Sep 15;84(6):766-74. doi: 10.1016/j.bcp.2012.06.019. Epub 2012 Jun 28.

19.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
20.

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.

Cancer Res. 2005 Feb 15;65(4):1541-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk